X4 Pharmaceuticals (XFOR) Tops Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts XFOR Hot Sheet
Join SI Premium – FREE
X4 Pharmaceuticals (NASDAQ: XFOR) reported Q1 EPS of $0.04, $0.16 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $28.81 million versus the consensus estimate of $12.03 million.
For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hillman Solutions (HLMN) Tops Q3 EPS by 1c; Offers Guidance
- National Presto Indust. (NPK) Reports Q3 EPS of $2.79
- ONE Gas (OGS) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
